Canada has become the third country to agree to take part in the worldwide trials that are planned for the new drug, which may prove to be effective against a range of cancers.
Developers, Zarix, of Berwin, Pennsylvania, USA, said their intention was to market the drug for treatment of liver cancer in the first instance.
More than 600 patients have already been treated in Phase II trials in North America and Europe. Other cancers against which the drug has been tested include pancreatic cancer and adenocarcinoma of the colon.
Phase II trials on hepatocellular carcinoma patients showed that the majority achieved a stable disease status.
Thymitaq - or nolatrexed dihydrochloride - is a novel thymidylate synthase inhibitor.
|Thymitaq is a novel thymidylate synthase inhibitor.|
Zarix intends that the multi-center Phase III study will cover North America, Europe, and South Africa.
Elizabeth Corsi, President of Zarix, said, "Thymitaq has a broad anticancer spectrum of activity.
"We intend to file our market applications for the treatment of unresectable hepatocellular carcinoma. However, as additional Phase III trials are completed, we will file supplemental applications for approvals in other indications."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com